Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

Open access
Dallinga-Thie, Geesje M., Kroon, Jeffrey, Borén, Jan, Chapman, M. John · 2016 · Current Cardiology Reports

Abstract

It is now evident that elevated circulating levels of triglycerides in the non-fasting state, a marker for triglyceride (TG)-rich remnant particles, are associated with increased risk of premature cardiovascular disease (CVD). Recent findings from basic and clinical studies have begun to elucidate the mechanisms that contribute to the atherogenicity of these apoB-containing particles. Here, we review current knowledge of the formation, intravascular remodelling and catabolism of TG-rich lipoproteins and highlight (i) the pivotal players involved in this process, including lipoprotein lipase, glycosylphosphatidylinositol HDL binding protein 1 (GPIHBP1), apolipoprotein (apo) C-II, apoC-III, angiopoietin-like protein (ANGPTL) 3, 4 and 8, apoA-V and cholesteryl ester transfer protein; (ii) key determinants of triglyceride (TG) levels and notably rates of production of very-low-density lipoprotein 1 (VLDL1) particles; and (iii) the mechanisms which underlie the atherogenicity of remnant particles. Finally, we emphasise the polygenic nature of moderate hypertriglyceridemia and briefly discuss modalities for its clinical management. Several new therapeutic strategies to attenuate hypertriglyceridemia have appeared recently, among which those targeted to apoC-III appear to hold considerable promise.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11886-016-0745-6

Cites

Statistics

Figures

Fig. 1 LPL is synthesised in parenchymal cells in muscle and adipose tissue and then transported to the endothelial cell surface. LPL-mediated TG lipolysis at this surface is the first essential step in TG homeostasis. TGs are hydrolysed by LPL bound to GPIHBP1 in a process that is dependent on apoC-II. ApoC-III and apoA-V are potential inhibitors of LPL-mediated lipolysis. Upon TG hydrolysis, free fatty acids are taken up by surrounding tissues
Fig. 1 LPL is synthesised in parenchymal cells in muscle and adipose tissue and then transported to the endothelial cell surface. LPL-mediated TG lipolysis at this surface is the first essential step in TG homeostasis. TGs are hydrolysed by LPL bound to GPIHBP1 in a process that is dependent on apoC-II. ApoC-III and apoA-V are potential inhibitors of LPL-mediated lipolysis. Upon TG hydrolysis, free fatty acids are taken up by surrounding tissuesCC BY · PubMed Central
Fig. 2 Transcytosis enable the influx of lipoproteins over the vessel wall. This process is mediated by clathrin. The average diameter of these transport vesicles are around 100 nm, which only allows transport of lipoproteins with the size of 70 nm or smaller, thereby excluding chylomicrons and large VLDL remnant particles. The average transport speed is around 2500 vesicles per minute. The retention of lipoproteins in the subendothelial space is mediated by the interaction between positively charged residues on apoB and apoE and the negatively charged sulphate groups in the glycosaminoglycans chains of HSPG expressed on the vessel wall
Fig. 2 Transcytosis enable the influx of lipoproteins over the vessel wall. This process is mediated by clathrin. The average diameter of these transport vesicles are around 100 nm, which only allows transport of lipoproteins with the size of 70 nm or smaller, thereby excluding chylomicrons and large VLDL remnant particles. The average transport speed is around 2500 vesicles per minute. The retention of lipoproteins in the subendothelial space is mediated by the interaction between positively charged residues on apoB and apoE and the negatively charged sulphate groups in the glycosaminoglycans chains of HSPG expressed on the vessel wallCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 94 · Cited by 90

Research works printed but not linked: 1

  1. Taskinen MR, Adiels M, Westerbacka J, et al. Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol. 2011;31:2144–50. · DOI · Paper page

Metadata

Authors
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J.
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Sahlgrenska University Hospital (SE)
  • Inserm (FR)
Venue
Current Cardiology Reports
Published
2016-05-23
Volume
18
Issue
7
Pages
67-67
ISSN
  • 1523-3782 (ISSN-L)
  • 1534-3170
OpenAlex
W2398962077
Cited by
90
References
94
Citations by year
2026: 4 · 2025: 7 · 2024: 4 · 2023: 9 · 2022: 6 · 2021: 14 · 2020: 11 · 2019: 11 · 2018: 17 · 2017: 6 · 2016: 1
FWCI
2.03
Type
journal article
Language
en
Open access
Locations
  • Current Cardiology Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
triglyceride-rich lipoproteins, hypertriglyceridemia, atherogenicity, cardiovascular risk, lipoprotein lipase, GPIHBP1, apolipoprotein C-II, apolipoprotein C-III, ANGPTL3, ANGPTL4, ANGPTL8, apolipoprotein A-V, cholesteryl ester transfer protein
MeSH terms
Hypolipidemic Agents, Cholesterol, Endothelium, Vascular, Humans, Lipoproteins, Triglycerides, Hypertriglyceridemia, Postprandial Period, Atherosclerosis, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? https://app.cochat.ai/papers/10.1007/s11886-016-0745-6
The paper
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016). Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? Current Cardiology Reports. https://doi.org/10.1007/s11886-016-0745-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.